Pediatric Protocol In Written Agreement Should Be Strictly Followed - FDA
Executive Summary
NDA sponsors will be expected to precisely adhere to study protocols included in pediatric written agreements, FDA's revised guidance on pediatric exclusivity states.
You may also be interested in...
Antihypertensive Pediatric Sample Request Describes "Meaningful" Data
FDA's sample written request for antihypertensive agent pediatric information specifies what types of studies will produce "meaningful" data for pediatric labeling.
Pediatric Data Not Included In Label May Be Made Public By Alternate Means
FDA may seek to disseminate data collected from pediatric studies by alternate methods if enough sponsors do not include the results in labeling, the agency's June 29 "Qualifying for Pediatric Exclusivity" guidance states.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011